View in EDS HTML Full Text PDF Full Text

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

Saved in:
Bibliographic Details
Title: Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
Authors: King B; Dermatology Physicians of Connecticut, Fairfield, CT, USA., McMichael A; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Sinclair R; Sinclair Dermatology, Melbourne, VIC, Australia., Vañó-Galvan S; Hair Disorders Unit at Ramón y Cajal University Hospital, IRYCIS, and Pedro Jaén Group Clinic, University of Alcalá, Madrid, Spain., Wolk R; Pfizer Inc., Groton, CT, USA., Woodworth D; Pfizer Inc., Collegeville, PA, USA., Soma K; Pfizer Inc., Groton, CT, USA., Robbana F; Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, H9J 2M5, Canada. Feriel.Robbana@pfizer.com., Lejeune A; Pfizer Inc., Paris, France., Napatalung L; Pfizer Inc., New York, NY, USA.; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Law E; Pfizer Inc., New York, NY, USA., Wajsbrot D; Pfizer Inc., Groton, CT, USA., Wang C; Pfizer Inc., Groton, CT, USA., Roychoudhury S; Pfizer Inc., New York, NY, USA.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2025 Dec; Vol. 15 (12), pp. 3793-3803. Date of Electronic Publication: 2025 Oct 14.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41083802
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22King+B%22">King B</searchLink>; Dermatology Physicians of Connecticut, Fairfield, CT, USA.<br /><searchLink fieldCode="AU" term="%22McMichael+A%22">McMichael A</searchLink>; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.<br /><searchLink fieldCode="AU" term="%22Sinclair+R%22">Sinclair R</searchLink>; Sinclair Dermatology, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Vañó-Galvan+S%22">Vañó-Galvan S</searchLink>; Hair Disorders Unit at Ramón y Cajal University Hospital, IRYCIS, and Pedro Jaén Group Clinic, University of Alcalá, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Wolk+R%22">Wolk R</searchLink>; Pfizer Inc., Groton, CT, USA.<br /><searchLink fieldCode="AU" term="%22Woodworth+D%22">Woodworth D</searchLink>; Pfizer Inc., Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Soma+K%22">Soma K</searchLink>; Pfizer Inc., Groton, CT, USA.<br /><searchLink fieldCode="AU" term="%22Robbana+F%22">Robbana F</searchLink>; Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, H9J 2M5, Canada. Feriel.Robbana@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Lejeune+A%22">Lejeune A</searchLink>; Pfizer Inc., Paris, France.<br /><searchLink fieldCode="AU" term="%22Napatalung+L%22">Napatalung L</searchLink>; Pfizer Inc., New York, NY, USA.; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Law+E%22">Law E</searchLink>; Pfizer Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wajsbrot+D%22">Wajsbrot D</searchLink>; Pfizer Inc., Groton, CT, USA.<br /><searchLink fieldCode="AU" term="%22Wang+C%22">Wang C</searchLink>; Pfizer Inc., Groton, CT, USA.<br /><searchLink fieldCode="AU" term="%22Roychoudhury+S%22">Roychoudhury S</searchLink>; Pfizer Inc., New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101590450%22">Dermatology and therapy</searchLink> [Dermatol Ther (Heidelb)] 2025 Dec; Vol. 15 (12), pp. 3793-3803. <i>Date of Electronic Publication: </i>2025 Oct 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare+Communications%22">Springer Healthcare Communications </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101590450 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2193-8210 (Print) <i>NLM ISO Abbreviation: </i>Dermatol Ther (Heidelb) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41083802
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13555-025-01543-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3793
    Titles:
      – TitleFull: Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: King B
      – PersonEntity:
          Name:
            NameFull: McMichael A
      – PersonEntity:
          Name:
            NameFull: Sinclair R
      – PersonEntity:
          Name:
            NameFull: Vañó-Galvan S
      – PersonEntity:
          Name:
            NameFull: Wolk R
      – PersonEntity:
          Name:
            NameFull: Woodworth D
      – PersonEntity:
          Name:
            NameFull: Soma K
      – PersonEntity:
          Name:
            NameFull: Robbana F
      – PersonEntity:
          Name:
            NameFull: Lejeune A
      – PersonEntity:
          Name:
            NameFull: Napatalung L
      – PersonEntity:
          Name:
            NameFull: Law E
      – PersonEntity:
          Name:
            NameFull: Wajsbrot D
      – PersonEntity:
          Name:
            NameFull: Wang C
      – PersonEntity:
          Name:
            NameFull: Roychoudhury S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2193-8210
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Dermatology and therapy
              Type: main
ResultId 1